Stocks & Investing
Thu, April 11, 2019
[ 12:00 AM ] - WOPRAI
Tue, November 13, 2018
[ 12:00 AM ] - WOPRAI
Thu, May 31, 2018
[ 12:00 AM ] - WOPRAI
Thu, January 4, 2018
Mon, November 13, 2017
[ 12:00 AM ] - WOPRAI
Tue, October 10, 2017
[ 12:00 AM ] - WOPRAI
Wed, August 16, 2017
Tue, April 1, 2014
[ 12:00 AM ] - WOPRAI
Fri, March 28, 2014
[ 12:00 AM ] - WOPRAI
Mon, March 3, 2014
[ 12:00 AM ] - WOPRAI
Tue, January 28, 2014
[ 12:00 AM ] - WOPRAI
Fri, October 25, 2013
Fri, May 25, 2012 Liav Abraham Maintained (TEVA) at Strong Buy with Decreased Target to $23 on, Apr 11th, 2019
Liav Abraham of Citigroup, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Strong Buy with Decreased Target from $27 to $23 on, Apr 11th, 2019.
Liav has made no other calls on TEVA in the last 4 months.
There are 6 other peers that have a rating on TEVA. Out of the 6 peers that are also analyzing TEVA, 4 agree with Liav's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Jacob Hughes of "Wells Fargo" Maintained at Hold with Decreased Target to $18 on, Wednesday, April 3rd, 2019
- David Risinger of "Morgan Stanley" Downgraded from Buy to Hold and Held Target at $17 on, Wednesday, March 6th, 2019
- Vamil Divan of "Credit Suisse" Maintained at Hold with Decreased Target to $20 on, Thursday, February 14th, 2019
- David Amsellem of "Piper Sandler" Upgraded from Sell to Hold and Increased Target to $16 on, Wednesday, January 23rd, 2019
These are the ratings of the 2 analyists that currently disagree with Liav
- Elliot Wilbur of "Raymond James" Upgraded from Hold to Buy on, Thursday, February 14th, 2019
- Jason Gerberry of "B of A Securities" Upgraded from Sell to Strong Buy on, Thursday, January 3rd, 2019
